Subdural hemorrhages in acute lymphoblastic leukemia: case report and literature review
© The Author(s) 2016
Received: 31 January 2016
Accepted: 27 July 2016
Published: 18 August 2016
Acute lymphoblastic leukemia is a rare hematological malignancy. Pure subdural hemorrhages in a patient with acute lymphoblastic leukemia patient are extremely rare.
This case presented acute spontaneous subdural hemorrhage without head trauma at first, and acute lymphoblastic leukemia was diagnosed later. The second time, the patient was admitted with multiple pure subdural hemorrhages in different locations and periods with a history of slight head trauma.
Pure subdural hemorrhages can occur in a patient with acute lymphoblastic leukemia. More care would be needed for pure subdural hemorrhages without obvious head trauma, and patients with hematological malignancies should be protected from even mild head trauma.
Leukemia, especially acute types, can lead to intracranial hemorrhage (ICH) with high morbidity and mortality [1, 2]. Chen CY et al. reported that ICH occurred in 2.8 % adult patients with hematological malignancies . But the main type of ICH was intraparenchymal hemorrhage, accounted for 74.5 % . Acute lymphoblastic leukemia (ALL) rarely resulted in pure subdural hemorrhage (SDH). This is the first report about several pure SDHs which included two acute types, separately without and with head trauma, and one chronic type in a patient with ALL according to previous literature reports.
Leukocyte count (153.9 × 109/L), platelet count (6.0 × 109/L), lymphocyte count (20.0 × 109/L), D-Dimer (6.98 mg/L), and erythrocyte count (1.97 × 1012/L) revealed aggravated condition. Fecal occult blood was positive with (+). The blood coagulation test was normal again. In addition to the symptomatic treatments, we advised specialized therapy of department of hematology, but her families rejected again. 1 month later, the patient died of multiple organ dysfunction syndrome (MODS) after long-term unconsciousness.
This case had repeated SDHs. The first one was acute and spontaneous without definite history of head trauma. The second time, she had two SDHs in different locations, which included an acute type and an unaware chronic type. These were all pure SDHs, which was very rare. In the study of Chen CY , the incidence of pure SDH was 0.47 % in patients with hematological malignancies. But repeated pure SDHs in ALL were never reported.
For tearing of the bridging and cortical veins, SDH could occur. Acute SDH often has a clear history of head trauma. Chronic SDH usually occurs after 3 weeks or even a longer time so that the history of head trauma may be forgotten. But in the patients with hematological malignancies, head trauma may be not a necessary cause, which was also proved through our case.
The possible risk factors of ICH caused by leukemia include thrombocytopenia, platelet dysfunction, disseminated intravascular coagulation (DIC), coagulation factor deficiency, hyperleukocytosis, vessel wall abnormalities, hypertension and sepsis [2, 4]. Our patient had thrombocytopenia all the time. ALL was getting worse that could be found in her laboratory data. The D-Dimer was getting higher, 3P tests were positive and fecal occult blood was positive with (+), which all revealed aggravated DIC.
Yhim HY et al. reported bilateral chronic subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia . Our patient had no chance of chromosome examination, but the clinical manifestations of her first acute SDH and the second chronic SDH were similar to that case. This may suggest the evolution of SDH in ALL patients even without dasatinib, that acute SDH in ALL may have a strong tendency to develop chronic SDH.
This patient had repeated SDHs without serious central nervous system involvement or surgery. This did not mean insignificant condition. Previous study had shown high mortality (50 %) among SDH patients with hematological malignancies . Each SDH, caused by hematological malignancy, may be also associated with a higher possibility of neurosurgery and potential adverse outcomes.
So far, there is still no effective way to prevent ICH, including SDH, in patients with hematological malignancies. Prophylactic platelet transfusions to maintain the platelet count at a safe threshold has been proved to be an effective treatment to decreased the risk of hemorrhagic complication with hematological malignancies . Considering the etiology of SDH, ALL patients should also be protected from even mild head trauma through our case.
Various types of pure SDHs in a patient with ALL are extremely rare. Acute pure SDH can occur in ALL patients without definite head trauma. Even if acute SDH was absorbed completely, secondary unaware chronic SDH could occur. Homonymous acute SDH and chronic SDH in different locations could coexist in ALL. Hematological malignancies should be considered when a patient, who had no obvious history of head trauma, came with acute SDH and low-grade fever. With the aggravation of ALL, worse laboratory data may suggest higher risk of chronic SDH after acute SDH. In addition to active diagnosis and treatment, ALL patients should be protected from even mild head trauma to avoid SDH for their tendency of hemorrhage.
ALL, acute lymphoblastic leukemia; CT, computed tomography; DIC, disseminated intravascular coagulation; ICH, intracranial hemorrhage; SDH, subdural hemorrhage
The authors wish to thank Yuan-Li Zhao MD, Professor, in the Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, for his support and enthusiasm.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Availability of data and materials
The manuscript does not include any new software, databases or all relevant raw data.
RY and CXQ contributed to write the report. RY, CXQ and XHD contributed in clinical treatment of the case. RY contributed in drafting the manuscript. RY and YLC contributed in revising the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
This case report has had consent to publish with our institutional consent form signed by her family members.
Ethics approval and consent to participate
The manuscript has had ethics approval and consent to participate by medical ethics committee of Huzhou Central Hospital.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, et al. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011;86:546–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim H, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS, et al. Risk score model for fatal intracranial hemorrhage in acute leukemia. Leukemia. 2006;20:770–6.View ArticlePubMedGoogle Scholar
- Chen CY, Tai CH, Cheng A, Wu HC, Tsay W, Liu JH, et al. Intracranial hemorrhage in adult patients with hematological malignancies. BMC Med. 2012;10:97.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen CY, Tai CH, Tsay W, Chen PY, Tien HF. Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia. Annals of Oncology. 2009;20:1100–4.View ArticlePubMedGoogle Scholar
- Yhim HY, Kim HS, Lee NR, Song EK, Kwak JY, Yim CY. Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. 2012;95:585–7.View ArticlePubMedGoogle Scholar
- Blajchman MA, Slichter SJ, Heddle NM, Murphy MF. New strategies for the optimal use of platelet transfusions. Hematology Am Soc Hematol Educ Program, 2008, 198–204. doi:10.1182/asheducation-2008.1.198.